Edition:
India

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

305.40CHF
23 Oct 2018
Change (% chg)

CHF-11.10 (-3.51%)
Prev Close
CHF316.50
Open
CHF311.50
Day's High
CHF311.50
Day's Low
CHF301.70
Volume
461,980
Avg. Vol
297,940
52-wk High
CHF342.00
52-wk Low
CHF218.00

Chart for

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 0.99
Market Cap(Mil.): CHF19,317.19
Shares Outstanding(Mil.): 74.47
Dividend: 2.55
Yield (%): 0.98

Financials

UPDATE 1-Lonza confirms targets as gets off to good start

ZURICH, May 4 Swiss drug ingredients maker Lonza confirmed its guidance on Friday and said it had got off to a good start this year.

04 May 2018

Lonza confirms targets as Q1 gets off to good start

ZURICH, May 4 Swiss drug ingredients maker Lonza confirmed its guidance on Friday and said it had got off to a good start this year.

04 May 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

03 May 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

03 May 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL, May 3 Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

03 May 2018

Accounting concerns wipe $6 billion off Samsung BioLogics market value

SEOUL South Korean biotech drug manufacturer Samsung BioLogics Co Ltd lost almost $6 billion in market value on Wednesday in its biggest intra-day share drop, after the country's financial watchdog said it breached accounting rules.

02 May 2018

UPDATE 3-Accounting concerns wipe $6 bln off Samsung BioLogics market value

* Financial watchdog gives preliminary notice to co on measures

02 May 2018

Earnings vs. Estimates